Literature DB >> 16238095

Role of the phosphatase PP4 in the activation of JNK-1 in prostate carcinoma cell lines PC-3 and LNCaP resulting in increased AP-1 and EGR-1 activity.

Juan Inostroza1, Leonardo Sáenz, Gloria Calaf, Gertrudis Cabello, Eduardo Parra.   

Abstract

The specific signaling connections between the mitogen-activated protein kinases (MAPK) such as c-Jun N-terminal kinase (JNK-1) and phosphatases PP4 and M3/6, affecting the family of early nuclear factors, is complex and remains poorly understood. JNK-1 regulates cellular differentiation, apoptosis and stress responsiveness by up-regulating early nuclear factors such as c-Jun, a member of the activating protein (AP-1) family, and the Early Growth Factor (EGR-1). C-Jun, when phosphorylated by c-Jun N-terminal kinase (JNK-1) associates with c-Fos to form the AP-1 transcription factor that activates gene expression. We have investigated the regulation of the JNK-1 kinase by co-transfecting phosphatases PP4 and M3/6 in prostate cancer cell lines PC-3 and LNCaP, which have been previously stimulated with human EGF or cisplatin. Co-transfections of plasmids expressing the JNK-1 and the serine/threonine phosphatases PP4 resulted in a significant increase in JNK-1 activity in both PC3 and LNCaP cells. In contrast, co-transfection of JNK-1 with the dual specific phosphatase serine/threonine M3/6 showed only a marginal effect in JNK-1 activity. The phosphatase M3/6 also failed in blocking the induction of JNK-1 activity observed in presence of PP4. The higher activity of JNK-1 was associated with increased activities of the factors c-Jun/AP-1 and EGR-1. This suggests that JNK-1 activity in PC-3 and LNCaP cells requires not only active PP4 for stable maintenance but also suggests that the relative degree of phosphorylation of multiple cellular components is the determinant of JNK-1 stability.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16238095     DOI: 10.4067/s0716-97602005000200006

Source DB:  PubMed          Journal:  Biol Res        ISSN: 0716-9760            Impact factor:   5.612


  6 in total

1.  Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.

Authors:  Shaofan Weng; Hua Wang; Weihong Chen; Matthew H Katz; Deyali Chatterjee; Jeffrey E Lee; Peter W Pisters; Henry F Gomez; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-04       Impact factor: 4.254

2.  The 2,6-disubstituted purine reversine induces growth arrest and polyploidy in human cancer cells.

Authors:  Tze-Chen Hsieh; Frank Traganos; Zbigniew Darzynkiewicz; Joseph M Wu
Journal:  Int J Oncol       Date:  2007-12       Impact factor: 5.650

3.  Pulsatile gonadotropin-releasing hormone stimulation of gonadotropin subunit transcription in rat pituitaries: evidence for the involvement of Jun N-terminal kinase but not p38.

Authors:  D J Haisenleder; L L Burger; H E Walsh; J Stevens; K W Aylor; M A Shupnik; J C Marshall
Journal:  Endocrinology       Date:  2007-10-11       Impact factor: 4.736

4.  Lentivirus-Mediated Short-Hairpin RNA Targeting Protein Phosphatase 4 Regulatory Subunit 1 Inhibits Growth in Breast Cancer.

Authors:  Yuying Qi; Tinghui Hu; Kai Li; Renqing Ye; Zuodong Ye
Journal:  J Breast Cancer       Date:  2015-09-24       Impact factor: 3.588

5.  Inhibition of Notch1 signaling overcomes resistance to the death ligand Trail by specificity protein 1-dependent upregulation of death receptor 5.

Authors:  A Fassl; K E Tagscherer; J Richter; J De-Castro Arce; C Savini; F Rösl; W Roth
Journal:  Cell Death Dis       Date:  2015-10-15       Impact factor: 8.469

Review 6.  Functional roles of protein phosphatase 4 in multiple aspects of cellular physiology: a friend and a foe.

Authors:  Jaehong Park; Dong-Hyun Lee
Journal:  BMB Rep       Date:  2020-04       Impact factor: 4.778

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.